Related Experiment Videos

Antimicrobial properties of liposomal polymyxin B

S M McAllister1, H O Alpar, M R Brown

  • 1SmithKline Beecham Pharmaceuticals, Drug Delivery Group, Harlow CM17 5AW, Essex.

Insights

Liposomal polymyxin B retains its antimicrobial activity against Pseudomonas aeruginosa, crucial for cystic fibrosis lung infections. Liposome surface properties influence bacterial interactions and drug efficacy.

Area of Science:

  • Pharmacology
  • Microbiology
  • Drug Delivery

Background:

  • Polymyxin B pulmonary residence time increases with liposomal formulation.
  • Liposomal polymyxin B holds promise for cystic fibrosis lung infections.
  • Antimicrobial activity must be preserved post-encapsulation.

Purpose of the Study:

  • Verify retained antimicrobial activity of encapsulated polymyxin B.
  • Assess bactericidal activity and MICs of free vs. encapsulated polymyxin B.
  • Investigate liposomal surface characteristics' role in bacterial interactions.

Main Methods:

  • Determined bactericidal activity and Minimum Inhibitory Concentrations (MICs).
  • Compared free and encapsulated polymyxin B formulations (neutral, negative, positive charges).
  • Investigated liposome-bacterial cell surface interactions.

Main Results:

  • Polymyxin B retained antimicrobial activity after encapsulation.
  • Positively and negatively charged liposomes showed potent bactericidal activity.
  • Neutral liposomes were less effective; surface charge and phospholipid composition influenced efficacy.

Conclusions:

  • Liposome encapsulation does not diminish polymyxin B's antimicrobial activity.
  • Liposome surface properties and drug release are key to bacterial interactions.
  • Optimized liposomal formulations may enhance polymyxin B efficacy for lung infections.

Related Concept Videos